Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-center, Non-randomized, and Open-label Phase I/IIa Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of ICP-490 in Patients With Relapsed and/or Refractory Multiple Myeloma

NCT05719701 is registered in ClinicalTrials.gov with Beijing InnoCare Pharma Tech Co., Ltd. as lead sponsor.

NCT NCT05719701
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05719701 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-center, Non-randomized, and Open-label Phase I/IIa Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of ICP-490 in Patients With Relapsed and/or Refractory Multiple Myeloma
Lead sponsor
Beijing InnoCare Pharma Tech Co., Ltd.
Phase
Phase 1/2
Overall status
Unknown status
Start date
March 29, 2023
Completion date
December 30, 2025
Enrollment
80 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

relapsed and/or refractory multiple myeloma